<DOC>
	<DOCNO>NCT01146509</DOCNO>
	<brief_summary>The purpose extension study evaluate safety efficacy donepezil hydrochloride extend use migraine prophylaxis . Efficacy continue evaluate .</brief_summary>
	<brief_title>An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride ( E2020 ) In Migraine Prophylaxis</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Patient must complete study E2020A001211 accord protocol . 2 . Male female patient 1865 year age . Women childbearing potential practiced effective contraception ( e.g. , abstinence , intrauterine device ( IUD ) barrier method plus hormonal method ) , negative urine hCG Week 0 , willing remain current form contraception duration study . Pregnant and/or lactate female exclude . 3 . Patients race generally good health . 4 . Patient willing participate , provide write informed consent prior expose studyrelated procedure . 1 . Evidence clinically significant disorder evaluate medically , show stable medication treatment ( ) period least 3 month , include active uncontrolled tumor , nontrauma related cerebrovascular accident , gastrointestinal , renal , hepatic , endocrine pulmonary disease , cardiovascular system disease know collagen vascular disease ( e.g. , systemic lupus erythematosus ) . Hypertension medication control ( supine diastolic BP &lt; 95 mmHg ) . Cardiac disease ( angina pectoris , congestive heart failure arrhythmia ) stable appropriate medication 6 month . No elective surgical procedure allow course study . 2 . Patients recent history ( &lt; /= 2 year ) active treatment hematologic/oncologic disorder ( basal squamous cell carcinoma skin ) . 3 . Patients serious central nervous system ( CNS ) disorder ( e.g. , neoplasm , infection , demyelinate disease , degenerative neurological disease Alzheimer 's disease , Parkinson 's disease , vascular dementia , progressive CNS disease ) either evidence focal neurological sign symptom examination history ( e.g. , papilledema ) evidence transient neurological symptom without ensue headache . 4 . Any medical psychiatric ( e.g. , severe depression , psychosis , bipolar disorder ) condition , opinion Investigator , make patient unsuitable study . 5 . History chronic alcoholism drug abuse define DSMIV criterion patient previously hospitalize and/or treat substance abuse within past one year . 6 . History overuse ( &gt; 12 day per four week period average ) acute headache medication include analgesic , opioids , Nonsteroidal antiinflammatory drug ( NSAIDs ) , butalbital contain compound , ergot triptans within past one ( 1 ) year . 7 . Patients take prior concomitant medication , define Protocol ( Appendix 16.1.1 ) , study . 8 . Patients unwilling unable fulfill requirement study . 9 . Patients know hypersensitivity piperidine derivative . 10 . Patients take cholinesterase inhibitor ( e.g. , donepezil , tacrine , rivastigmine , galantamine , metrifonate ) acute prophylactic treatment migraine past ( exclude E2020A001211 ) currently take cholinesterase inhibitor indication . 11 . Patients take unapproved prior concomitant medication . In particular , patient allow take betablockers , tricyclic antidepressant , calcium channel blocker , monoamine oxidase inhibitor , valproate , methysergide , cyproheptadine ongoing prophylactic treatment migraine participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>migraine</keyword>
	<keyword>headache</keyword>
</DOC>